Lineage Cell Therapeutics
LCTX
80 hedge funds and large institutions have $153M invested in Lineage Cell Therapeutics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 8 closing their positions.
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
53% more capital invested
Capital invested by funds: $99.9M → $153M (+$53.2M)
8% more funds holding
Funds holding: 74 → 80 (+6)
0.61% more ownership
Funds ownership: 42.79% → 43.4% (+0.61%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
68% less call options, than puts
Call options by funds: $103K | Put options by funds: $318K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$869K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$647K |
| 3 |
Jane Street
New York
|
+$267K |
| 4 |
State Street
Boston,
Massachusetts
|
+$222K |
| 5 |
D.E. Shaw & Co
New York
|
+$206K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pointe Capital Management
Grosse Pointe Farms,
Michigan
|
-$204K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$123K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$75.8K |
| 4 |
ST
Spot Trading
Chicago,
Illinois
|
-$60.3K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$58K |
LCTX Hedge Fund Activity: Q3 2016 in Review
80 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2016, worth a combined $153M — up 53% from $99.9M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LCTX positions and 8 closed out — a net gain of 6 holders — while 27 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $869K. The largest seller was Pointe Capital Management, exiting entirely with an estimated $204K sold.
- 80 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2016, up from 74 in Q2 2016.
- Funds reported $153M of Lineage Cell Therapeutics stock for Q3 2016, up 53% quarter-over-quarter.
- 14 funds opened new Lineage Cell Therapeutics positions in Q3 2016 and 8 closed out, a net change of +6 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $869K added.
- The largest Lineage Cell Therapeutics seller in Q3 2016 was Pointe Capital Management, an estimated $204K sold.
Based on aggregated 13F filings for Q3 2016.